---
slug: selank-benzodiazepines
title: "selank benzodiazepines"
kind: standard
status: published
hash: 3319bddbd4d99288b369fc65dbef155ce935f1de19d68ade363872f3cfaeb0b0
created: 2026-06-29T17:54:46.727Z
updated: 2026-10-08T11:49:27.959Z
summary: "benzodiazepines represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether selank mechanisms address underlying repair deficits. Studied for anxiolytic pathways without classic"
tags: ["peptide"]
above: []
below: []
adjacent: []
nested: []
---
# selank benzodiazepines

*benzodiazepines represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether selank mechanisms address underlying repair deficits. Studied for anxiolytic pathways without classic*

## Regeneration vs degeneration — where this fits

benzodiazepines represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether selank mechanisms address underlying repair deficits.

## What is known

Studied for anxiolytic pathways without classic benzodiazepine sedation.

Target condition: benzodiazepines.
Body system: GABAergic suppression; does not rebuild neurochemistry..

## Logic chain

1. selank studied for anxiolytic pathways without classic benzodiazepine sedation..
2. benzodiazepines involves gabaergic suppression; does not rebuild neurochemistry. dysfunction.
3. If selank reaches the affected tissue, it may shift the repair/breakdown balance.
4. This chain is tested in animal or lab models only.

## Parent peptide claims relevant here

- In a 2008 randomized study of 62 patients with GAD and neurasthenia, Selank showed anxiolytic efficacy comparable to medazepam on psychometric scales without reported sedation, cognitive impairment, tolerance or withdrawal.
- Selank administration in rats alters expression of 45 neurotransmission-related genes at 1 hour and 22 genes at 3 hours, with positive correlation to GABA effects.
- Commercial vendors and clinics market this compound (7 commercial/clinic sources catalogued) — marketing material, not evidence.
- 2017 study showing Selank's anxiolytic effects comparable to benzodiazepines in rat stress model.
- 2019 rat study on Selank protecting against alcohol-related memory issues via BDNF regulation.

## Evidence tier

Preclinical — animal and in vitro studies only. No published human trials for this specific combination.

## What we do not know

- Whether selank reaches benzodiazepines tissue at functional concentrations
- Optimal dosing, route, and duration for this target
- Interaction with standard-of-care treatments for benzodiazepines
- Long-term safety profile in this population

## Safety note

All peptide use for benzodiazepines is research-context only. Not medical advice. Consult a physician before any experimental compound.

## Facts

```json
{
  "converted_from": "markdown",
  "original_updated": "2026-07-17T02:41:35.052Z",
  "register": "standard",
  "category": null
}
```

## Sources

1. [Combined Action of Benzodiazepine Tranquilizers and Peptide Anxiolytic Selank in BALB/с Mice](https://link.springer.com/article/10.1134/S1819712425700783) — “Thus, it has been shown in animal experiments that selank enhances the anxiolytic effect and decreases the sedative and myorelaxant action of benzodiazepine tranquilizers.” (sha256 c933904249c4fc72)